Unknown PHASE2 INTERVENTIONAL 1-arm NCT01083719

A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.

Phase II Study Comparing FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.

Sponsor: Medanta Institute of Clinical Research

Conditions Glioblastoma

Interventions FDG-PET

Updated 5 times since 2017 Last updated: Mar 9, 2010 Started: Apr 30, 2010 Primary completion: Aug 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01083719, this PHASE2 trial focuses on Glioblastoma and remains ongoing. Sponsored by Medanta Institute of Clinical Research, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medanta Institute of Clinical Research

Data source: Medanta Institute of Clinical Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.